There are currently threeFDA-approved semaglutideproducts: As the world's first and currently onlyweekly glucagon-like peptid-1 receptor agonist (GLP-1RA) formulation forlong-term weight management, Semaglutideweight loss achieves an average weight loss of 17% (16.8kg) and providespatients with multiple health benefits beyond weight loss
Even more remarkable is that the 4mg arm, starting losing weight again as well
Research shows that Mounjaro can help control appetite, improve energy levels, and make long-term weight management more achievable than dieting alone
In the SURMOUNT3 trial, individuals who received tirzepatide after a comprehensive 12week lifestyle intervention achieved a mean 25% weight reduction, compared to 4.8% in the placebo group [178], suggesting a benefit for staged lifestyle intervention with GLP1s
Quick Recovery: Most patients return to normal activities within a day or two
May help lower blood pressure and reduce the risk of heart disease
